PS
LGND icon

Portfolio Solutions’s Ligand Pharmaceuticals LGND Stock Holding History

Portfolio Solutions’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-80
Closed -$8K – 116
2018
Q1 		$8K Hold
80
– – ﹤0.01% 134
2017
Q4 		$7K Hold
80
– – ﹤0.01% 141
2017
Q3 		$7K Hold
80
– – ﹤0.01% 136
2017
Q2 		$6K Hold
80
– – ﹤0.01% 135
2017
Q1 		$5K Buy
+80
New +$5.26K ﹤0.01% 166

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Portfolio Solutions's LGND Position: Q2 2018 in Review

Portfolio Solutions sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 80 shares — an estimated $8K sold.

Portfolio Solutions first reported a position in LGND in Q1 2017 and held it in 5 quarters. The position peaked at $8K in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

  • Portfolio Solutions reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Portfolio Solutions sold 80 Ligand Pharmaceuticals shares in Q2 2018, an estimated $8K.
  • Portfolio Solutions first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 5 quarters.
  • Portfolio Solutions's Ligand Pharmaceuticals position peaked at $8K in Q1 2018.
  • 346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Portfolio Solutions's 13F filing for Q2 2018, filed 13 Jul 2018.